FDA said it is reviewing reports of mood changes, suicidal behavior and suicide in patients who have taken the drug, which was Merck's best-selling product last year.

In the past year Merck has updated the drug's labeling four times to include information on tremors, anxiousness, depression and suicidal behavior reported in some patients.

Singulair had sales of $4.3 billion last year.